Large UK study finds no benefit to HIV antiviral in COVID-19

The results are the third significant clinical finding from the RECOVERY study, which recently determined the steroid dexamethasone improved survival.

By Ned Pagliarulo • June 30, 2020

Third patient dies in halted study of Audentes gene therapy

The three patients, treated for a rare neuromuscular disease, were given a high dose of Audentes' gene therapy.

By Ben Fidler • Updated Aug. 21, 2020

Explore the Trendline➔

Cell therapy

The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases.

By BioPharma Dive staff

WHO lays out ambitious plan to deliver 2 billion coronavirus vaccine doses

More than $18 billion will be needed for the WHO's plan, which would secure and allocate vaccine supplies for high-risk groups and lower-income countries.

By Ned Pagliarulo • June 26, 2020

Clinical trials are only getting more complex, and wishful thinking has to go

If you look at the data trends over the last decade, there's no avoiding the truth: clinical trials are getting more complex every year.

By Natania Barron Global Director, Marketing • June 26, 2020

Fauci 'cautiously optimistic' about coronavirus vaccine by 2021

Anthony Fauci, the nation's top infectious disease official, told lawmakers the next few weeks will be critical as COVID-19 cases rise in many states.

By Rebecca Pifer • June 24, 2020

NIH ends key COVID-19 studies of hydroxychloroquine

The agency stopped one trial because the malaria drug didn't appear to be helping patients, and halted the second because few people were enrolling.

By Jonathan Gardner • June 22, 2020

Merck gives 1st look at Phase 3 results for its Prevnar competitor

Results from two late-stage studies of V114, Merck's experimental pneumococcal conjugate vaccine, could help support a submission for approval later this year.

By Ned Pagliarulo • June 22, 2020

UniQure gets out the gate first in race for Huntington's gene therapy

The biotech has dosed patients in the first trial of a gene-targeted treatment for the degenerative disease, but competitor Voyager could be chasing soon.

By Jonathan Gardner • June 19, 2020

Chinese biotech to test GSK, Dynavax adjuvants in coronavirus vaccine study

A Phase 1 study of Clover Biopharmaceuticals' experimental vaccine will also test technologies used to boost the body's immune response to inoculation.

By Ned Pagliarulo • June 19, 2020

In big year for microbiome drugs, a small biotech sets the bar

Data from Finch Therapeutics will likely be held up against two rivals planning to present their own clinical results later this year. 

By Jacob Bell • June 19, 2020

Cheap steroid lowers risk of death in hospitalized COVID-19 patients, U.K. study finds

The results from the RECOVERY trial were one of the few bright spots over the summer, when vaccines were still in testing and doctors the world over were desperate for effective treatments.

By Jonathan Gardner • June 16, 2020

Lilly claims success in early breast cancer study, leaping past Pfizer

The results for Lilly's Verzenio come just weeks after Pfizer's drug Ibrance fell short in a similar trial, and sent shares in the Indianapolis drugmaker soaring.

By Ben Fidler • June 16, 2020

Informing parents and protecting children as they navigate pediatric trials

As the RACE Act prompts the need for more pediatric research, parents will need adequate time to ask questions, stay informed and ensure that their child is protected in a clinical trial.

June 16, 2020

Magenta's technology attracts another gene therapy developer

A freshly inked research pact will test one of biotech's antibody drug conjugates as a conditioning treatment for patients receiving Beam Therapeutics' gene editing therapies.

By Jacob Bell • June 15, 2020

Sinovac claims progress with early coronavirus vaccine study

The Chinese drugmaker said trial results showed its vaccine spurred immune responses, with no serious side effects, but offered little data to support the claim.

By Ned Pagliarulo • June 15, 2020

CureVac gets German backing for coronavirus vaccine, but says it's independent

An investment of 300 million Euros gives the German government a 23% stake in CureVac, but won't grant the country exclusive national rights to a vaccine nearing human testing.

By Jonathan Gardner • June 15, 2020

Agios, seeking a new strategy, touts positive data and marketing deal

The company has sold off royalty rights to one of its drugs amid a push to focus on a wholly owned medicine it's developing for several blood diseases.

By Jacob Bell • June 12, 2020

New CRISPR, gene therapy results strengthen potential for treatment of blood diseases

CRISPR Therapeutics and Vertex can more convincingly say their CRISPR-based medicine is helping three people with beta thalassemia or sickle cell disease, while Bluebird takes another step forward.

By Ned Pagliarulo • June 12, 2020

Moderna to start in July what could be first late-stage coronavirus vaccine trial

The Phase 3 study, which would be run in collaboration with the NIH, is expected to enroll 30,000 participants in the U.S. Other similarly large studies of candidates from AstraZeneca and J&J could quickly follow.

By Ben Fidler • June 11, 2020

Regeneron brings first COVID-19 antibody 'cocktail' into human tests

The biotech has begun a pair of clinical trials testing a two-drug combination in COVID-19 patients. Two other studies, starting later this month, aim to prove the therapy can prevent coronavirus infections.

By Ben Fidler • June 11, 2020

Drug regulators in agreement on coronavirus vaccine trials, FDA official says

Health agencies will be under pressure to clear promising vaccines quickly. But Peter Marks, a top FDA official, said regulators will still want to see large trials to provide proof of safety.

By Jonathan Gardner , Ben Fidler • June 9, 2020

AstraZeneca, already a leader in coronavirus vaccine race, steps up antibody drug work

The British drugmaker has licensed six potential COVID-19 antibodies from Vanderbilt, and could start testing the first of them by early August.

By Ben Fidler • June 9, 2020

Coronavirus vaccines are rolling out quickly. Here's where the pipeline stands.

Fuller data in hand, Pfizer and BioNTech plan to soon seek full U.S. approval for their vaccine in 12- to 15-year-olds. 

By Ned Pagliarulo, Jonathan Gardner, Shoshana Dubnow, Ben Fidler, Nami Sumida • Updated Nov. 24, 2021

Alnylam details data for kidney disease drug under FDA review

Treatment with lumasiran significantly lowered levels of a key chemical correlated with kidney failure, paving the way for what would be Alnylam's third drug approval.

By Jonathan Gardner • June 8, 2020

Lilly gets a 2nd COVID-19 antibody into clinical trials with Junshi's help

The trial start comes days after Lilly began U.S. testing of a similar drug it developed with AbCellera, putting the Indianapolis pharma at the forefront of efforts to engineer antibodies against the new coronavirus. 

By Ned Pagliarulo • June 8, 2020